DR-106 Discovery of mutational signatures associated with chemotherapeutic treatment of cancer
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-106 Discovery of mutational signatures associated with chemotherapeutic treatment of cancer
Mutational signatures are patterns of mutations that inform us on the mutational process underlying tumorigenesis. We will investigate the mutational …
DR-104 A comprehensive analysis of mutational processes and signatures in primary and metastatic cancer tumors
Systematic analysis of cancer genomes has revealed a number of characteristic mutational signatures. Some of these have been linked to …
DR-103 BRAF and RNF43 copy number variation and mutant allele frequency in BRAF/RNF43 mutant colorectal cancer.
An aggressive subtype of colorectal cancer (CRC) harbours activating mutations in the BRAF oncogene and inactivating mutations in the RNF43 …
DR-102 Correlation analyses of genomic data, ctDNA and clinical data in patients with advanced/metastatic urothelial cell cancer (UCC) treated with anti-PD1 checkpoint inhibitors.
The treatment of bladder cancer patients with immunotherapy is a very promising and effective treatment. However, only a minority of …
DR-101 Analysis of high resolution whole-genome sequencing (WGS) data to define structural rearrangements and copy number signatures-based associated with DNA repair deficiencies in metastatic castration resistant prostate cancer (mCRPC).
The purpose of our project is to derive genomic signatures based on presence of structural rearrangements and copy number from …
DR-132 ctDNA analysis to monitor response to neoadjuvant chemoradiation in esohageal cancer patients
“After treatment with a combination of chemotherapy and radiotherapy for esophageal cancer, the current standard treatment is to continue with …
DR-131 The link between the immunologic and genomic characteristics of patients with metastatic melanoma and the possible effect on response to (immuno)therapy.
“Since almost 10 years, the outcome of patients with metastatic melanoma has improved significantly and long term durable responses have …
DR-129 Comparing metastatic and primary breast tumours through the lens of integrated subtypes
The Personalised Breast Cancer Program (PBCP) is an initiative based at the Cancer Research UK Cambridge Institute and the Addenbrooke’s …
DR-127 “Genetic causes of resistance to new androgen receptor signaling inhibitors in metastasized castration-resistant prostate cancer patients. DR-127 is an extension of DR-013”
“Androgen receptor inhibitors (ARi) are frequently used to treat metastatic prostate carcinomas. In this project, we focus on identifying genetic …
DR-125 Characterizing genome instability profiles in human cancers
We aim to understand the molecular mechanisms leading to the high degree of mutability observed in certain types of tumors …
DR-123 Pan-cancer RNA landscape analysis to explain functional changes, identify novel biomarkers and therapeutic targets
We recently finalized an extensive genomic analysis of breast and prostate cancer, which provided important novel insights into the biology …
DR-121 Refining the candidate identification of germline and somatic variation with a functional role in metastatic cancers
Priestley et al. (2019), the study introducing the Hartwig Medical Foundation data collection, used several state-of-the-art analysis tools for calling …
Een complete genetische analyse zou onderdeel moeten zijn van de standaarddiagnostiek bij iedere patiënt met kanker. Dat draagt bij aan een beter, afgestemd behandeladvies. Zo verminderen we over- en onderbehandeling, maken we tegelijkertijd de zorg kosten-effectiever en houden we hem betaalbaar.